{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:00:32Z","timestamp":1776394832656,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04877-3","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:37:01Z","timestamp":1766129821000},"page":"8049-8059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Calcitonin gene-related peptide antagonists in Raynaud\u2019s phenomenon: a disproportionality study based on real data and drug-gene network analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Haibin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0710-3231","authenticated-orcid":false,"given":"Yan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-3934","authenticated-orcid":false,"given":"Xiaolan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"1","key":"4877_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"M Arnold","year":"2018","unstructured":"Arnold M (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"8","key":"4877_CR2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/03331024221077646","volume":"42","author":"M Ashina","year":"2022","unstructured":"Ashina M, Mcallister P, Cady R et al (2022) Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: post hoc analysis of PROMISE-1 and PROMISE-2. Cephalalgia 42(8):696\u2013704. https:\/\/doi.org\/10.1177\/03331024221077646","journal-title":"Cephalalgia"},{"key":"4877_CR3","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2025.017","author":"S Barnes","year":"2025","unstructured":"Barnes S, Aldous L, Jenkins B (2025) Calcitonin gene-related peptide--targeted therapies for migraine. Aust Prescr. https:\/\/doi.org\/10.18773\/austprescr.2025.017","journal-title":"Aust Prescr"},{"issue":"5","key":"4877_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0333102420983282","volume":"41","author":"M Bhakta","year":"2021","unstructured":"Bhakta M, Vuong T, Taura T et al (2021) Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia 41(5):499\u2013514. https:\/\/doi.org\/10.1177\/0333102420983282","journal-title":"Cephalalgia"},{"issue":"4","key":"4877_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/1523-1747.ep12455620","volume":"84","author":"SD Brain","year":"1986","unstructured":"Brain SD, Tippins JR, Morris HR et al (1986) Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 84(4):533\u2013536. https:\/\/doi.org\/10.1111\/1523-1747.ep12455620","journal-title":"J Invest Dermatol"},{"key":"4877_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7934","volume":"4","author":"ID Breen","year":"2021","unstructured":"Breen ID, Brumfiel CM, Patel MH et al (2021) Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open 4:e217934. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7934","journal-title":"JAMA Netw Open"},{"key":"4877_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93307-b","author":"C Bunker","year":"1990","unstructured":"Bunker C, Dowd P, Terenghi G et al (1990) Deficiency of calcitonin gene-related peptide in Raynaud\u2019s phenomenon. Lancet. https:\/\/doi.org\/10.1016\/0140-6736(90)93307-b","journal-title":"Lancet"},{"issue":"4","key":"4877_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ et al (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64(4):333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"issue":"1","key":"4877_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/pds.5548","volume":"32","author":"A Coste","year":"2023","unstructured":"Coste A, Wong A, Bokern M et al (2023) Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review. Pharmacoepidemiol Drug Saf 32(1):28\u201343. https:\/\/doi.org\/10.1002\/pds.5548","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10200","key":"4877_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X","journal-title":"Lancet"},{"issue":"2","key":"4877_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaad.2022.06.1199","volume":"90","author":"P Curtiss","year":"2024","unstructured":"Curtiss P, Svigos K, Schwager Z et al (2024) Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud\u2019s phenomenon. J Am Acad Dermatol 90(2):223\u2013234. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1199","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4877_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0333102417736900","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Warfvinge K (2019) Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 39(3):366\u2013373. https:\/\/doi.org\/10.1177\/0333102417736900","journal-title":"Cephalalgia"},{"key":"4877_CR13","doi-asserted-by":"publisher","unstructured":"Evans RW (2019) Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache 59(8):1360\u20131364. https:\/\/doi.org\/10.1111\/head.13596","DOI":"10.1111\/head.13596"},{"key":"4877_CR14","doi-asserted-by":"publisher","DOI":"10.1139\/y95-152","author":"G Feuerstein","year":"1995","unstructured":"Feuerstein G, Willette R, Aiyar N (1995) Clinical perspectives of calcitonin gene related peptide pharmacology. Can J Physiol Pharmacol. https:\/\/doi.org\/10.1139\/y95-152","journal-title":"Can J Physiol Pharmacol"},{"key":"4877_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0951-2","author":"S F\u00f6rderreuther","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL et al (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-018-0951-2","journal-title":"J Headache Pain"},{"issue":"000","key":"4877_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fnmol.2024.1355281","volume":"17","author":"K Frimpong-Manson","year":"2024","unstructured":"Frimpong-Manson K, Ortiz YT, Mcmahon LR et al (2024) Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics. Front Mol Neurosci 17(000):26. https:\/\/doi.org\/10.3389\/fnmol.2024.1355281","journal-title":"Front Mol Neurosci"},{"key":"4877_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2368817","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Raschi E, Poluzzi E et al (2024) The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2368817","journal-title":"Expert Opin Drug Saf"},{"key":"4877_CR18","doi-asserted-by":"publisher","unstructured":"Gaag AVD, Fipp SPC, Fipp MPS, et al. 2025 12. Vascular pain: Ischemic pain in the extremities and Raynaud's syndrome. Pain Practice 25(1):e13421.https:\/\/doi.org\/10.1111\/papr.13421","DOI":"10.1111\/papr.13421"},{"key":"4877_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01424-w","author":"AO G\u00e9rard","year":"2022","unstructured":"G\u00e9rard AO, Merino D, Van Obberghen EK et al (2022) Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-022-01424-w","journal-title":"J Headache Pain"},{"key":"4877_CR20","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, et al. (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurol 95(18). https:\/\/doi.org\/10.1212\/WNL.0000000000010600","DOI":"10.1212\/WNL.0000000000010600"},{"issue":"2","key":"4877_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3892\/etm.2019.7656","volume":"18","author":"J Guan","year":"2019","unstructured":"Guan J, Lin H, Xie M et al (2019) Higenamine exerts an antispasmodic effect on cold-induced vasoconstriction by regulating the PI3K\/Akt, ROS\/\u03b12C-AR and PTK9 pathways independently of the AMPK\/eNOS\/NO axis. Exp Ther Med 18(2):1299\u20131308. https:\/\/doi.org\/10.3892\/etm.2019.7656","journal-title":"Exp Ther Med"},{"issue":"6","key":"4877_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P et al (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93(6):539\u2013546. https:\/\/doi.org\/10.1038\/clpt.2013.24","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4877_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40120-021-00234-7","volume":"10","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, Dodick DW, Treppendahl C et al (2021) Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther 10(1):235\u2013249. https:\/\/doi.org\/10.1007\/s40120-021-00234-7","journal-title":"Neurol Ther"},{"key":"4877_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18773\/austprescr.2020.047","volume":"43","author":"B Jenkins","year":"2020","unstructured":"Jenkins B (2020) Migraine management. Aust Prescr 43:148\u2013151. https:\/\/doi.org\/10.18773\/austprescr.2020.047","journal-title":"Aust Prescr"},{"issue":"2","key":"4877_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/head.14258","volume":"62","author":"AK Kawata","year":"2022","unstructured":"Kawata AK, Ladd MK, Lipton RB et al (2022) Reducing the physical, social, and emotional impact of episodic migraine: results from erenumab STRIVE and ARISE phase III randomized trials. Headache 62(2):159\u2013168. https:\/\/doi.org\/10.1111\/head.14258","journal-title":"Headache"},{"key":"4877_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12912","author":"C Khouri","year":"2016","unstructured":"Khouri C, Blaise S, Carpentier P et al (2016) Drug-induced Raynaud\u2019s phenomenon: beyond \u03b2-adrenoceptor blockers. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.12912","journal-title":"Br J Clin Pharmacol"},{"key":"4877_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1055\/a-1942-6823","volume":"4","author":"D Kopel","year":"2022","unstructured":"Kopel D, Gottschalk C (2022) The epidemiology of primary headache disorders. Semin Neurol 4:449\u2013458. https:\/\/doi.org\/10.1055\/a-1942-6823","journal-title":"Semin Neurol"},{"key":"4877_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2080381","author":"A Krymchantowski","year":"2022","unstructured":"Krymchantowski A, Silva-N\u00e9to RP, Jevoux C et al (2022) Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. Postgrad Med. https:\/\/doi.org\/10.1080\/00325481.2022.2080381","journal-title":"Postgrad Med"},{"key":"4877_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, Maassenvandenbrink A, Deligianni CI et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24:56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1","journal-title":"J Headache Pain"},{"key":"4877_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-87421-w","author":"N Lee","year":"2025","unstructured":"Lee N, Ok JH, Rhee S-j et al (2025) Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-025-87421-w","journal-title":"Sci Rep"},{"key":"4877_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1431562","volume":"15","author":"Q Liang","year":"2024","unstructured":"Liang Q, Liao X, Wu H et al (2024) Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases. Front Pharmacol 15:1431562. https:\/\/doi.org\/10.3389\/fphar.2024.1431562","journal-title":"Front Pharmacol"},{"key":"4877_CR32","doi-asserted-by":"publisher","DOI":"10.1159\/000489958","author":"X-P Lin","year":"2018","unstructured":"Lin X-P, Cui H-J, Yang A-L et al (2018) Astragaloside IV improves vasodilatation function by regulating the PI3K\/Akt\/eNOS signaling pathway in rat aorta endothelial cells. J Vasc Res. https:\/\/doi.org\/10.1159\/000489958","journal-title":"J Vasc Res"},{"issue":"3","key":"4877_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22(3):209\u2013217. https:\/\/doi.org\/10.1016\/S1474-4422(22)00517-8","journal-title":"Lancet Neurol"},{"issue":"2","key":"4877_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210212","volume":"104","author":"RB Lipton","year":"2025","unstructured":"Lipton RB, Gandhi P, Tassorelli C et al (2025) Early improvements with atogepant for the preventive treatment of migraine: results from 3 randomized phase 3 trials. Neurology 104(2):e210212. https:\/\/doi.org\/10.1212\/WNL.0000000000210212","journal-title":"Neurology"},{"key":"4877_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2053149","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang S, Xue J et al (2019) CGRP reduces apoptosis of DRG cells induced by high-glucose oxidative stress injury through PI3K\/AKT induction of heme oxygenase-1 and Nrf-2 expression. Oxid Med Cell Longev 2019:2053149. https:\/\/doi.org\/10.1155\/2019\/2053149","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"4877_CR36","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.neurom.2024.08.005","volume":"27","author":"J Maciaczyk","year":"2024","unstructured":"Maciaczyk J, Bara G, Basilaia B et al (2024) A prospective single-center pilot study on the use of closed-loop spinal cord stimulation to treat chronic pain associated with Raynaud\u2019s phenomenon. Neuromodulation 27(8):1457\u20131469. https:\/\/doi.org\/10.1016\/j.neurom.2024.08.005","journal-title":"Neuromodulation"},{"issue":"8","key":"4877_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4625","volume":"9","author":"AH Manickam","year":"2021","unstructured":"Manickam AH, Buture A, Tomkins E et al (2021) Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine. Clin Case Rep 9(8):e04625. https:\/\/doi.org\/10.1002\/ccr3.4625","journal-title":"Clin Case Rep"},{"key":"4877_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-025-01365-4","author":"KS Nicol","year":"2025","unstructured":"Nicol KS, Burkett JG (2025) Review: an update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine. Curr Pain Headache Rep. https:\/\/doi.org\/10.1007\/s11916-025-01365-4","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"4877_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad120","volume":"24","author":"F Noor","year":"2023","unstructured":"Noor F, Asif M, Ashfaq UA et al (2023) Machine learning for synergistic network pharmacology: a comprehensive overview. Brief Bioinform 24(3):bbad120. https:\/\/doi.org\/10.1093\/bib\/bbad120","journal-title":"Brief Bioinform"},{"key":"4877_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241297688","author":"F Puledda","year":"2024","unstructured":"Puledda F, De Boer I, Messina R et al (2024) Worldwide availability of medications for migraine and tension-type headache: a survey of the International Headache Society. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024241297688","journal-title":"Cephalalgia"},{"issue":"2","key":"4877_CR41","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644. https:\/\/doi.org\/10.1152\/physrev.00059.2021","journal-title":"Physiol Rev"},{"issue":"8676","key":"4877_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/s0140-6736(89)91966-1","volume":"2","author":"S Shawket","year":"1989","unstructured":"Shawket S, Hazleman B, Dickerson C et al (1989) Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud\u2019s phenomenon. Lancet 2(8676):1354\u20131357. https:\/\/doi.org\/10.1016\/s0140-6736(89)91966-1","journal-title":"Lancet"},{"key":"4877_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2248877","author":"R Singh","year":"2024","unstructured":"Singh R, Kumar A, Lather V et al (2024) Identification of novel signal of Raynaud\u2019s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2023.2248877","journal-title":"Expert Opin Drug Saf"},{"key":"4877_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2010.12.002","author":"S-J Smillie","year":"2011","unstructured":"Smillie S-J, Brain SD (2011) Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides. https:\/\/doi.org\/10.1016\/j.npep.2010.12.002","journal-title":"Neuropeptides"},{"key":"4877_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00038-3","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, Seeher KM, Schiess N et al (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3","journal-title":"Lancet Neurol"},{"key":"4877_CR46","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2023","unstructured":"Sun W, Li Y, Xia B et al (2023) Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front Pharmacol 14:1257282. https:\/\/doi.org\/10.3389\/fphar.2023.1257282","journal-title":"Front Pharmacol"},{"key":"4877_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07429","author":"M Tanaka","year":"2021","unstructured":"Tanaka M, Matsumoto K, Satake R et al (2021) Gentamicin-induced hearing loss: a retrospective study using the Food and Drug Administration Adverse Event Reporting System and a toxicological study using drug\u2212gene network analysis. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07429","journal-title":"Heliyon"},{"issue":"6","key":"4877_CR48","first-page":"425","volume":"30","author":"TF Tannahill","year":"1888","unstructured":"Tannahill TF (1888) Raynaud\u2019s disease, or local asphyxia and symmetrical gangrene of the extremities. Glasgow Med J 30(6):425\u2013429","journal-title":"Glasgow Med J"},{"issue":"10483","key":"4877_CR49","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U et al (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet 405(10483):1014\u20131026. https:\/\/doi.org\/10.1016\/S0140-6736(25)00109-6","journal-title":"Lancet"},{"issue":"10","key":"4877_CR50","doi-asserted-by":"publisher","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Liang C-S, Chang C-M et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2128544\u2013e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544","journal-title":"JAMA Netw Open"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04877-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:37:29Z","timestamp":1776393449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04877-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4877"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04877-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require institutional ethics committee approval because the analysis was carried out on an anonymized and publicly accessible pharmacovigilance database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}